Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: A safe and efficacious 12-month treatment for melasma

Cutis

Volumn 75, Issue 1, 2005, Pages 57-62

  Torok, Helen Mary ^a,f,g   Jones, Terry ^b   Rich, Phoebe ^c   Smith, Stacy ^d,f   Tschen, Eduardo ^e  

^a HMT Dermatology Associates Inc   (United States)

^b J and S Studies   (United States)

^c Northwest Cutaneous Research Specialists   (United States)

^d Therapeutics Inc   (United States)

^e Academic Dermatology Associates   (United States)

^f Galderma Pharmaceuticals   (United States)

^g Trilium Creek Dermatology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; HYDROQUINONE; RETINOIC ACID; TRI LUMA;

ACNE; ADULT; ARTICLE; ATROPHY; BODY WEIGHT; BURNING SENSATION; CHLOASMA; CLINICAL TRIAL; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; PERIORAL DERMATITIS; PHYSICIAN; ROSACEA; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN EXFOLIATION; TELANGIECTASIA;

ANTIOXIDANTS; DRUG COMBINATIONS; FACIAL DERMATOSES; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; HYDROQUINONES; KERATOLYTIC AGENTS; MALE; MELANOSIS; MIDDLE AGED; OINTMENTS; TREATMENT OUTCOME; TRETINOIN;

EID: 13544262499     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
2. Katsambas A, Antoniou C. Melasma: classification and treatment. J Eur Acad Dermatol Venereol. 1995;4:217-223.
3. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698-710.
4. Taylor SC. Epidemiology of skin diseases in people of color. Cutis. 2003;71:271-275.
5. Vasquez M, Maldonado H, Benmaman C, et al. Melasma in men. Int J Dermatol. 1988;27:25-27.
6. Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48:S143-S148.
7. Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982;20:55-58.
8. Vazquez M, Sanchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis. 1983;32:92, 95-96.
9. Denton CR, Lerner AB, Fitzpatrick TB. Inhibition of melanin formation by chemical agents. J Invest Dermatol. 1952;18:119-135.
10. Jimbow K, Obata H, Pathak MA, et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62:436-449.
11. Penney KB, Smith CJ, Allen JC. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes. J Invest Dermatol. 1984;82:308-310.
12. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894-899.
13. Pathak MA, Fitzpatrick TB, Paresh JA. Treatment of melasma with hydroquinone. J Invest Dermatol. 1993;76:324-329.
14. Haddad AL, Matos LF, Brunstein F, et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol. 2003;42:153-156.
15. Engasser PG, Maibach HJ. Cosmetics and dermatology: bleaching creams. J Am Acad Dermatol. 1981;5:143-147.
16. Griffiths CE, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma. a vehicle-controlled, clinical trial. Br J Dermatol. 1993;129:415-421.
17. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients, a vehicle-controlled clinical trial. Arch Dermatol. 1994;130:727-733.
18. Craven NM, Griffiths CE. Topical retinoids and cutaneous biology. Clin Exp Dermatol. 1996;21:1-10.
19. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996;135:60-64.
20. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
21. Gano SE, Garcia RL. Topical tretinoin, hydroquinone, and betamethasone valerate in the therapy of melasma. Cutis. 1979;23:239-241.
22. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol. 1998;25:587-596.
23. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.
24. Berardesca E, Maibach H. Ethnic skin: overview of structure and function. J Am Acad Dermatol. 2003;48 (suppl 6):S139-S142.
25. Giannotti B, Melli MC. Current approaches to the treatment of melasma. Clin Drug Invest. 1995;10:57-64.
26. Kligman LH, Schwartz E, Lesnik RH, et al. Topical tretinoin prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect. Curr Probl Dermatol. 1993;21:79-88.